B+
Bull case
20%
Probability
Target price
$15.00
Analysis reference price unavailable
Analysis 2026-10-10 · RankAlpha Sentiment Codex
ARDT
Ardent HealthANYSE / Health Care Equipment & Services
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
50%
Probability
Target price
$12.50
Analysis reference price unavailable
Analysis 2026-10-10 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$8.50
Analysis reference price unavailable
Analysis 2026-10-10 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-10-10
Recent news sentiment (30D)
-26.0
Negative
Company
-
Unavailable
Macro
-26.0
Negative
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+51.6
Score
AI commentary
Primary evidence is mixed: reaffirmed guidance and higher savings expectations are constructive, but volume weakness and the September non-GAAP revision warrant caution. No attributable post-revision price reaction or verified analyst revisions were supplied. The numerical sentiment fields are unavailable inputs, not neutral or measured zero readings; recent headline coverage is thin.
RankAlpha Sentiment Codex - 2026-10-10
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-12-31catalystScrutiny of revised 2025 non-GAAP measuresHigh impact
Following discussions with SEC staff, Ardent removed $97.7 million of adjustments from its 2025 presentation, reducing adjusted EBITDA from $545.0 million to $447.3 million. The company said GAAP statements and 2026 results were unaffected. The risk is reduced confidence in historical non-GAAP comparability; the date is a monitoring horizon, not an announced event [#8-K-2026-09-04].
2027-03-31eventTest of reaffirmed 2026 guidanceHigh impact
Ardent reaffirmed 2026 revenue guidance of $6.4–$6.7 billion and adjusted EBITDA guidance of $485–$535 million despite a lower volume outlook. Q2 admissions fell 1.0% year over year, while adjusted admissions rose 2.5%. Subsequent results will test whether operating actions offset weaker surgeries and admissions; the date is a monitoring horizon [#SEC-8K-2026-08-04].
2027-03-31catalystDelivery of increased IMPACT savings targetMedium impact
Management raised expected 2026 IMPACT savings to at least $70 million from $55 million. Demonstrated savings could support margins, but must be evaluated alongside patient-volume pressure rather than treated as incremental earnings in isolation [#SEC-8K-2026-08-04].
Recommendation
N/A
No formal recommendation provided.
As of 2026-10-10 • Updated nightlySource: Internal modelMethodology